Researchers who have worked on GLP-1 obesity drugs are exploring a new approach that does not involve targeting GLP-1. Meanwhile, other developments related to GLP-1 and obesity treatment are ongoing, including the potential benefits and risks of existing GLP-1 medications. The broader context of obesity treatment and drug development is also being discussed, with some focusing on the limitations of current approaches and others on new possibilities.